Premium
The Zucker Diabetic Fatty (ZDF)rat as a model for assessment of anti‐diabetic therapies (LB766)
Author(s) -
Cornicelli Joseph,
Rocheford Erik,
Fisher Diane,
Countey Barbara,
SpencerPierce Jennifer,
Hoffman Jay,
Barry MaryEllen,
Dhawan Rajeev
Publication year - 2014
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.28.1_supplement.lb766
Subject(s) - medicine , metformin , pioglitazone , diabetes mellitus , sitagliptin , glycemic , insulin , endocrinology , type 2 diabetes
Diabetes and obesity have taken on epidemic proportions worldwide. In order to develop effective therapies against these disorders, translatable animal models that closely mimic the human disease are necessary for assessing therapeutic potential. The Zucker diabetic fatty (ZDF) rat is obese, hyperglycemic, insulin resistant and hyperlipidemic. This study defined the development of the diabetic phenotype in this model and assessed the activity of the standard anti‐diabetic treatments metformin, glyburide, pioglitazone, sitagliptin, as well as the anti‐inflammatory agent salsalate in this animal model over time. Pioglitazone was most effective in increasing glycemic control as measure by fasting and non‐fasting blood glucose, glucose tolerance and insulin tolerance. Metformin also improved glycemic control, although much more modestly. Glyburide exacerbated the diabetic phenotype in the rats, presumably by accelerating insulin secretion and beta cell failure. Interestingly, the anti‐inflammatory agent salsalate also improved the response to an insulin tolerance test. Assessment of various further support the notion that the ZDF rat can be used to assess agents designed to treat diabetes.